Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer
- 31 January 1999
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 72 (1) , 60-64
- https://doi.org/10.1006/gyno.1998.5237
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.Journal of Clinical Oncology, 1997
- Clinical trials in patients with epithelial ovarian cancer: past, present and futureEuropean Journal of Surgical Oncology, 1996
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Second‐line chemotherapy for recurrent carcinoma of the ovaryCancer, 1993
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982
- Reporting results of cancer treatmentCancer, 1981
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958